Want to see GB:OPTI full AI Analyst Report?
Top Page
OptiBiotix Health
(LSE:OPTI)
Select Model
Select Model
Rating:47Neutral
Price Target:
6.00 p
▲(6.19% Upside)
Action:Reiterated
Date:09/18/26
The score is held back primarily by persistent losses and continued cash burn despite improving gross margins and strong recent revenue growth. Technicals are broadly neutral with only modest positive momentum, while valuation is constrained by negative earnings and no stated dividend yield.
Positive Factors
Strong Revenue Growth
The sharp increase in 2025 revenue indicates stronger commercial traction for the company’s probiotic and microbiome products. If partner-led launches and customer demand continue, this growth can provide greater operating leverage and support broader market penetration over the next several quarters.
Negative Factors
Persistent and Widening Losses
Continuing losses show that revenue growth has not yet translated into a viable earnings model. With operating costs still scaling faster than revenue, the company may need sustained growth or further cost discipline before its commercial progress produces durable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
The sharp increase in 2025 revenue indicates stronger commercial traction for the company’s probiotic and microbiome products. If partner-led launches and customer demand continue, this growth can provide greater operating leverage and support broader market penetration over the next several quarters.
Read all positive factors
OptiBiotix Health (OPTI) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£6.04M
Dividend YieldN/A
Average Volume (3M)240.22K
Price to Earnings (P/E)―
Beta (1Y)0.46
Revenue Growth11.90%
EPS Growth-2864.29%
CountryUK
Employees9
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.04
Shares Outstanding103,300,300
10 Day Avg. Volume94,794
30 Day Avg. Volume240,215
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.09
Price to Sales (P/S)5.86
P/FCF Ratio-3.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
OptiBiotix Health Business Overview & Revenue Model
Company Description
OptiBiotix Health Plc, a life sciences enterprise headquartered in York, United Kingdom, specializes in the discovery and advancement of microbiome-modulating technologies. The company formulates distinct microbial strains, innovative compounds, a...
How the Company Makes Money
OptiBiotix primarily makes money by commercialising its probiotic and microbiome-related intellectual property through business-to-business arrangements rather than operating as a large-scale consumer brand owner. Key revenue streams include: (1) ...
OptiBiotix Health Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
63
Positive
Cash Flow
27
Negative
| Breakdown | TTM | Dec 2025 | Jun 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.29M | 1.17M | 870.00K | 644.00K | 457.00K | 2.21M |
| Gross Profit | 586.00K | 614.00K | 331.00K | 320.00K | 244.00K | 1.12M |
| EBITDA | -2.24M | -2.93M | -2.06M | -1.84M | 2.75M | 6.51M |
| Net Income | -4.29M | -3.89M | -1.80M | -2.04M | 2.59M | 6.26M |
Balance Sheet | ||||||
| Total Assets | 5.17M | 6.89M | 9.04M | 9.40M | 11.55M | 20.14M |
| Cash, Cash Equivalents and Short-Term Investments | 989.00K | 1.04M | 739.00K | 635.00K | 1.05M | 2.01M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 819.36K |
| Total Liabilities | 442.00K | 610.00K | 647.00K | 532.00K | 643.00K | 1.97M |
| Stockholders Equity | 4.73M | 6.28M | 8.40M | 8.87M | 10.90M | 18.14M |
Cash Flow | ||||||
| Free Cash Flow | -834.00K | -1.77M | -1.77M | -1.53M | -1.28M | -1.76M |
| Operating Cash Flow | -1.71M | -1.77M | -1.77M | -1.53M | -1.11M | -1.56M |
| Investing Cash Flow | 1.40M | 1.35M | 587.00K | 1.11M | -331.00K | -193.51K |
| Financing Cash Flow | 0.00 | 713.00K | 1.28M | 0.00 | 485.00K | 2.90M |
OptiBiotix Health Technical Analysis
Negative
5.65
Price Trends
5.83
Positive
5.96
Negative
6.04
Negative
Market Momentum
-0.01
Positive
46.25
Neutral
27.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:OPTI, the sentiment is Negative. The current price of 5.65 is below the 20-day moving average (MA) of 6.03, below the 50-day MA of 5.83, and below the 200-day MA of 6.04, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 46.25 is Neutral, neither overbought nor oversold. The STOCH value of 27.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:OPTI.
OptiBiotix Health Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | £15.55M | -33.33 | -5.25% | ― | 95.16% | 85.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | £6.04M | -1.41 | -77.85% | ― | 11.90% | -2864.29% | |
44 Neutral | £3.26M | -0.35 | -152.41% | ― | -70.77% | 60.39% | |
42 Neutral | £4.92M | -1.80 | -93.92% | ― | ― | 55.56% | |
42 Neutral | £3.54M | -2.88 | -83.53% | ― | ― | 93.02% | |
41 Neutral | £6.37M | -8.82 | 192.61% | ― | ― | 42.86% |
* Healthcare Sector Average
GB:OPTI
OptiBiotix Health
5.85
-4.90
-45.58%
GB:TCF
Evgen Pharma
0.18
-0.04
-18.18%
GB:FUM
Futura Medical
0.22
-3.01
-93.19%
GB:NFX
Nuformix Plc
0.14
-0.06
-29.32%
GB:CIZ
Cizzle Biotechnology Holdings PLC
1.50
0.10
7.14%
GB:SBTX
SkinBioTherapeutics
6.00
-8.88
-59.66%
OptiBiotix Health Corporate Events
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
OptiBiotix boosts H1 sales, cuts costs and secures new SlimBiome deals
Positive
Sep 17, 2026
OptiBiotix Health reported a 21.9% rise in first-half 2026 revenues to £679,000 and a 25.4% increase in gross profit, while cutting selling, RD and operating costs and lifting margins. Strong growth in Asia and other Rest of World markets off...
Business Operations and StrategyExecutive/Board Changes
OptiBiotix adds taste industry veteran to drive SweetBiotix push
Positive
Sep 15, 2026
OptiBiotix Health has appointed industry veteran Imad Farhat as a non-executive director of its wholly owned subsidiary OptiBiotix Ltd, which houses the SlimBiome, SweetBiotix and microbiome modulating technology platforms. Farhat brings more than...
Business Operations and StrategyProduct-Related Announcements
OptiBiotix advances SweetBiotix sugar substitute toward commercial production
Positive
Sep 8, 2026
OptiBiotix Health has provided an update on its SweetBiotix range, a portfolio of sweet fibres designed to act as healthy sugar substitutes while supporting gut health. The business aims to leverage these microbiome-focused sweeteners to capture d...
Business Operations and StrategyProduct-Related Announcements
OptiBiotix Taps GLP-1 Boom With Holland & Barrett FORMI Launch
Positive
Sep 2, 2026
OptiBiotix Health has expanded its presence in the weight management segment through the launch of Holland Barrett’s new FORMI Weight Loss Complex, which contains its clinically validated SlimBiome formulation. The product, sold as raspberr...
Business Operations and StrategyProduct-Related Announcements
OptiBiotix to brief investors after SweetBiotix sampling success
Positive
Jun 26, 2026
OptiBiotix Health will host a live investor presentation and QA on 2 July 2026 via its Investor Hub, following successful SweetBiotix sampling on 24 June. Chief executive Stephen O’Hara will update investors on the commercial progress of fir...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.